anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A simple cellulose sulphate based microencapsulation technology has been applied to encapsulate bacterial or other microbial cells, which produce and release digestive enzymes and thereby provides an acid resistant shelter for these microbial cells. Surprisingly, the resulting spheres were found to provide sufficient protection for encapsulated cells from treatment with aqueous acidic solutions. Thereby the cellulose sulphate microencapsulated cells, such as probiotics are now enabled to survive passage, for example, through the stomach after consumption by a human or animal with a higher survival rate than those not within a microcapsule. After passing the stomach these cells are delivering products produced by them, e.g. enzymes or other nutrition factors. This technology therefore proves to be very useful in providing digestive or otherwise beneficial enzymes and/or of living microbial cells, into the lower gastrointestinal tract, where they could confer their health benefit to the host.
There will be 3 dose groups, 1 to 3 with escalating antigen dose with PIKA adjuvant in sequential cohorts. Arm B2 will enroll subjects who received mRNA vaccines and will comprise of 15 subjects per dose. In arm B2, fifteen eligible subjects in each dose group will receive the study vaccine on Study Days 0 via intramuscular injection in alternative deltoid muscles.
Myocardial perfusion reserve is the ratio of global myocardial blood flow at stress vs. rest. Traditionally, it has been measured non-invasively using quantitative positron emission tomography (PET) or cardiac magnetic resonance (CMR). Several recent studies have suggested that measurement of myocardial perfusion reserve provides significant additive prognostic information during stress perfusion imaging in patients with known or suspected coronary artery disease. Myocardial perfusion reserve depends not only on trans-stenotic pressure gradient of the epicardial arteries and thus stenosis severity but even more on the ability of the coronary microvasculature (especially the pre-arterioles) to dilate. Therefore, coronary microvascular dysfunction, which impairs pre-arteriolar function, reduces myocardial perfusion reserve independently of the presence of epicardial coronary stenosis. Hence, the ability to measure myocardial perfusion reserve allows a more comprehensive assessment of the entire coronary circulation, beyond the current paradigm of the epicardial arteries.

However, both PET and current CMR techniques are cumbersome, and in the case of PET require radiation as well as on-site Rubidium-82 generators. Therefore, they are challenging for routine clinical practice and have been limited to specialized research centers. An alternative, simple CMR method for measurement of myocardial perfusion reserve by quantifying change in coronary sinus flow has been described. The coronary sinus drains approximately 96% of total myocardial blood flow and provides a potentially convenient location for measurement of global myocardial blood flow. This method has been validated against both invasive and PET techniques. The investigators hypothesized that measurement of coronary sinus flow at stress and rest may provide a simple and rapid assessment of myocardial perfusion reserve during regadenoson stress perfusion CMR.

This study will use phase contrast images obtained from patients during their clinically indicated CMR stress study to calculate myocardial perfusion reserve as the ratio of maximum myocardial blood flow to baseline blood flow - at the coronary sinus. Coronary sinus flow will be calculated by post-processing of images after the patient has left the scanner. In brief, the contour of the coronary sinus will be traced on the flow images throughout the cardiac cycle. Coronary sinus flow is calculated by integrating the momentary flow rate values from each cardiac phase over the entire cardiac cycle and multiplying by the mean heart rate during the acquisition. Patients will be followed for the occurrence of major adverse cardiac events (death, myocardial infarction, late revascularization, hospitalization for heart failure or unstable angina).
PROBLEM TO BE SOLVED: To obtain a low-toxic optically active isocoumarin derivative having immunomodulatory activity and neovascularization inhibitory activity by reaction of the racemic modification of an isocoumarin derivative with an optically active phenylethylamine. SOLUTION: The optical resolution of an isocoumarin derivative comprises the following steps: the racemic modification of an isocoumarin derivative of the formula is reacted with an optically active 1-phenylethylamine in an organic solvent (e.g. dioxane) to form and crystallize the diastereomer salt of one of the optically active modifications of the isocoumarin derivative of the formula and the optically active 1-phenylethylamine;  and the diastereomer is then fractionally collected and subsequently decomposed with an acid (e.g. hydrochloric acid) or a base to obtain the objective optically active isocoumarin derivative, wherein, in the isocoumarin derivative of the formula where R is methyl group, to obtain the S-modification (+), 1-phenylethylamine of R- modification (+) is pref. used at 0.3-0.6 molar time the isocoumarin derivative, and the operation is conducted pref. at room temperature (15-25 deg.C) for about 1-3 h under agitation.
The combined physical and cognitive activity VR arm will participate in our customized spatial navigation program that increases difficulty and length per trial over time. As described in the Game Design section, each session will consist of 5 trials. The first trial will be a long-delay free recall condition from the previous day's path. The next 4 trials will consist of learning, cued recall, and free recall. This VR-based spatial navigation program has been tested in our feasibility trial for safety and tolerability in older adults.
Disclosed in the present invention are a photosensitizer molecule and the use thereof in the increase of the retention time thereof in a tumor and the enhancement of the therapy for large-volume tumors, which belong to the field of nano-materials. According to the present invention, AN-BDP is synthesized by means of introducing anthracene into BODIPY-meso, and due to the strong intermolecular π-π interaction of anthracene, AN-BDP and an amphiphilic block copolymer DSPE-PEG 2000 are self-assembled into stable nanoparticles AN-BDP NPs. In addition, by means of anthracene, AN-BDP can be excited to a triplet excited state under light irradiation and acts with O 2 to generate 1O2. AN-BDP NPs are enriched at the tumor site and retained for around 10 days after tail vein injection. In a mouse tumor model having a conventional volume tumor, AN-BDP NPs can completely inhibit the growth of the tumor by means of one-time tail vein injection and one-time photoirradiation therapy; and in a large-volume tumor model, only a tumor growth inhibition rate of 12% is observed under the same therapy conditions. Due to the fact that the retention time thereof in a tumor is long, photoirradiation therapy can be carried out three times after a single injection of the AN-BDP NPs, and the therapeutic effect is remarkably improved.
Renal fibrosis is a key feature of chronic kidney disease (CKD) progression, whereas no proven effective anti-fibrotic treatments. Forsythiaside A (FTA), derived from Forsythia suspense, has been found to possess nephroprotective properties. However, there is limited research on its anti-fibrotic effects, and its mechanism of action remains unknown. This study aimed to investigate the suppressive effects of FTA on renal fibrosis and explore the underlying mechanisms. In vitro, we established a HK2 cell model induced by transforming growth factor β1 (TGF-β1), and in vivo, we used a mice model induced by unilateral ureteral obstruction (UUO). CCK-8 assay, qRT-PCR, Western blotting, immunofluorescence, flow cytometry, histological staining, immunohistochemistry, TUNEL assay, RNA transcriptome sequencing, and molecular docking were performed. The results showed that FTA (40 μM or 80 μM) treatment improved cell viability and suppressed TGF-β1-induced fibrotic changes and partial epithelial-mesenchymal transition (EMT). Furthermore, FTA treatment reversed the activation of the PI3K/AKT signaling pathway, and THBS1 was identified as the target gene. We found that THBS1 knockdown suppressed the activation of the PI3K/AKT signaling pathway and reduced the fibrosis and partial EMT-related protein level. Conversely, THBS1 overexpression activated the PI3K/AKT signaling pathway and exacerbated renal fibrosis and partial EMT. In vivo, mice were administered FTA (30 or 60 mg/kg) for 2 weeks, and the results demonstrated that FTA administration significantly mitigated tubular injury, tubulointerstitial fibrosis, partial EMT, and apoptosis. In conclusion, FTA inhibited renal fibrosis and partial EMT by targeting THBS1 and inhibiting activation of the PI3K/AKT pathway.
A robot system that includes a remote control station and a robot that has a camera, a monitor and a microphone. The robot includes a user interface that allows a user to link the remote control station to access the robot. By way of example, the user interface may include a list of remote control stations that can be selected by a user at the robot site to link the robot to the selected control station. The user interface can display a connectivity prompt that allows a user at the robot site to grant access to the robot. The connectivity prompt is generated in response to a request for access by a remote control station. The robot may include a laser pointer and a button that allows a user at the robot site to turn the laser pointer on and off.
Participants in Group A will receive Virtual Reality (VR) training with Routine physical therapy for every alternate day (3 days per week) for 6 weeks. Total number of sessions will be 18.
AIM: Early diagnosis of acute pancreatitis is crucial, and urinary trypsinogen has been recently reported as a useful biomarker for diagnosing acute pancreatitis. We aimed to evaluate the impact of renal dysfunction on the diagnostic performance of urinary trypsinogen-2 for acute pancreatitis.
METHODS: We conducted a retrospective study using the clinical data of patients who visited the Department of Emergency and Critical Care at the University of Tokyo Hospital between 1 October, 2021, and 30 June, 2022. Patients with available data on qualitative urinary trypsinogen-2 levels were identified. We compared the urinary trypsinogen-2 levels among patients who were clinically diagnosed with acute pancreatitis. We further stratified the patients according to renal function parameters, such as serum creatinine level, blood urea nitrogen level, and estimated glomerular filtration rate, and evaluated the performance of urinary trypsinogen-2 as a biomarker for acute pancreatitis.
RESULTS: Within 9 months, 35 patients were identified. Of them, 22 patients showed positive results and 13 showed negative results on the urinary trypsinogen-2 test. The sensitivity, specificity, positive predictive value, and negative predictive value were 0.80, 0.40, 0.18, and 0.92, respectively. Based on the blood urea nitrogen level and estimated glomerular filtration rate, the prevalence of false-positive results was significantly higher in patients with reduced renal function than in those with normal renal function.
CONCLUSION: In patients with reduced renal function, the urinary trypsinogen-2 qualitative test results might be interpreted with caution when used for diagnosing acute pancreatitis.
This disclosure provides, in certain embodiments, methods for generating and using extracts of  Pyrularia  ( e.g., Pyrularia pubera ) and/or an epiphytic/endophytic bacteria associated therewith, either alone or in combination with conventional immunostimulant(s) or anti-inflammatory agents, for modulation of the immune system of a subject. Also provided are compositions that include specific  Pyrularia  extracts, bacteria isolated from  Pyrularia  tissue (in particular,  Pantoea  species), and extracts of from such bacteria. Also provided herein are purified components of  Pyrularia  extracts and/or extracts from the epiphytic/endophytic bacteria, which extracts exhibit mitogenic or cytotoxic activities. Compositions provided herein can be used for the treatment of neutropenia subsequent to chemotherapy, and for the treatment of immune deficiency ( e.g. , such as is caused by toxic chemotherapy, disease, or advancing age), as well as in other immune- stimulatory methods. Other embodiments of the invention provide methods of producing extracts of the invention, as well as purified bioactive components thereof, including particularly bacterial LPS.
PROBLEM TO BE SOLVED: To obtain a temperature-sensitive composition giving excellent temperature-sensitive action when it is applied, a temperature-sensitive composition for aerosol, and a temperature-sensitive aerosol product surely giving excellent temperature-sensitive action together with sufficiently utilizing its content. SOLUTION: This temperature-sensitive composition is composed of 5-50 wt.% of powder of a hydrated heat-generating material comprising inorganic salts dispersed into an anhydrous but water-miscible liquid medium by a dispersant. A foaming agent in an amount of 1-15 wt.% may be contained in the composition. A temperature-sensitive composition for aerosol contains 1-10 wt.% of propellant. A temperature-sensitive aerosol product is filled in a two- pack type aerosol container in a state that a first agent comprising the temperature-sensitive composition for aerosol is separated from a second agent comprising a water-containing liquid for exothermic reaction mutually each other. Preferably, the liquid for exothermic reaction comprises a thickener- containing water.
Approval from Ethical Committee of Faculty of Medicine University of Indonesia was acquired prior conducting the study. Subjects were given informed consent before enrolling the study. Subjects identification was done using identification form, medical record, Mini Mental State Evaluation (MMSE) and Internal Classification of Diseases (ICD) 10. Subjects' anxiety level were measured using Amsterdam Preoperative Anxiety and Information Scale (APAIS) with the help of the researcher to explain the questions. Then, education were given to the subjects, guided by a flow chart made by the researcher, using verbal and emphatic non-verbal language. If during education subjects got anxious with or without cardiovascular emergencies, education would be stopped, subjects would be eased down. Subject's family would be called in. If the subjects agreed to continue, the study would be carried on, otherwise subjects were dropped out. Benzodiazepin and midazolam 0.5 mg/kgBW would be considered and consulted to a psychiatrist. On the day after the education and discussion, subjects filled in APAIS again before entering the operation room. APAIS score recorded before and after anesthesia would be presented in the means, and analyzed by SPSS using paired T-test (or Wilcoxon test as the alternative test).
Lower Extremity ROM exercise will be performed for 20 minutes each at the beginning of the hour until the end of each eye session, examination and session in the case visits. "Piper's Fatigue Scale" and Hemodialysis Comfort Scale", which are part of data collection, will be applied again at the end of the 1st and 2nd week after the sessions begin. The individual's life segments will be tracked and recorded at each session.
Here we describe a methodology to generate non virulent microorganisms from pathogenic ones through permanent genetic modification of the physical state of their membrane (MPS). Thus, at the onset of infection, in these transformed organisms. as they infect a host (e.g. a target cell of a higher eukaryote, particularly mammals, and more specifically human cells, or injecting them, in a model of animal infection, the expression of heat shock (stress) genes and the accumulation of the coded proteins (stress proteins or HSPs) and that of other species-specific gene products, the regulation is altered as a consequence of the modification of MPS. Among others, we refer also to genes whose regulation is mediated by signaling transduction pathways. Therefore, as a result of this procedure, pathogens became non-virulent (attenuated, live microorganisms) that can be osed for vaccine production.
Participants will be assigned to sequentially or in parallel escalating dose/regimen cohorts of ASP2074 in three parts (Part A, B and C). Part B and Part C will be opened sequentially based upon sponsor review of emerging data.
To collaboratively develop the implementation intervention with 2 clinic teams associated with the ATN (Phase 2). A formative evaluation will be done to provide local diagnostic data regarding barriers and facilitators to adoption and create development panels - local development teams made up of clinicians and administrators from the site, and study staff to address barriers and facilitators from formative evaluation and draft locally-customized clinical care and multi-level implementation strategies with initial sustainability plans.
BACKGROUND: Accurate benchmarking of outcomes after elective open total arch replacement is important for surgical decision making and for comparisons with emerging endovascular technologies.
METHODS: A multicentre registry of consecutive aortic arch procedures in 9 centres across Canada contained 250 elective total arch replacements from 2010 to 2021. A total of 728 patients undergoing elective hemiarch replacement over the same time period was used as a comparator group. Propensity score matching was used to construct 202 well matched pairs.
RESULTS: Patients undergoing total arch replacement were 63.2 ± 13.6 years old, and 34% were female. These patients were more likely to have connective tissue disorders compared with patients undergoing hemiarch replacement. When under hypothermic circulatory arrest, the total arch group uniformly used antegrade cerebral perfusion with median nadir temperature of 24°C (interquartile range [IQR] 21-25°C), and median duration 33 minutes (IQR 23-51 minutes). Before matching, in-hospital mortality and stroke rates were 5.2% and 10%, respectively, for the total arch group. After matching, the total arch group had in-hospital mortality similar to the hemiarch group (P = 0.58). Rates of stroke were also not statistically different (P = 0.11). The total arch group was more likely to experience delirium, prolonged intubation, increased intensive care unit length of stay, and transfusions.
CONCLUSIONS: Elective total arch replacement is performed with good in-hospital mortality rates that are similar to rates after elective hemiarch repairs. However, total arch replacement was associated with significantly higher rates of other morbidities, including delirium and prolonged intubation.
The hypothesis for this study is that Mannitol cream will reduce post long run pain more than vehicle cream alone. In this parallel design, 170 runners who usually experience a pain level greater than 5/10 on a numerical rating scale from 0 to 10 where zero is no pain and 10 is the worst pain ever, will be given a cream containing 25% mannitol to apply on one leg and the vehicle cream to apply on the other leg. The cream assignment will be randomized, and the runner, the person supplying the cream and the person inputting the data will be blinded as to which leg received which cream. Pain levels in each leg following the long run will be recorded, via an e-mail questionnaire, or, failing this, by telephone, the day of the run, and each day, for five days following the run. Mean and standard deviations for pain levels will be calculated for each treatment leg, and a repeated measures ANOVA (Analysis Of VAriance) will be done comparing the pain levels in each leg over the six days. Using this information, if the NRS (Numeric rating scale) pain levels differ by more than 1/10 between the two groups, a larger study will be conducted using the information gathered in this study to determine sample size.
Functional hypothalamic amenorrhea (FHA) is a common cause of amenorrhea and chronic anovulation in adolescent girls and young women, diagnosed after excluding other organic causes. It is commonly associated with calorie restriction, excessive physical exercise, and psychosocial stress. These stressors alter the pulsatile secretion of gonadotropin-releasing hormone, leading to a chronic condition of hypoestrogenism and significant health consequences. Recent evidence has highlighted a genetic predisposition to FHA that could explain interindividual variability in stress response. Indeed, not all women experience FHA in response to stress. Rare variants in genes associated with idiopathic hypogonadotropic hypogonadism have been identified in women with FHA, suggesting that these mutations may contribute to an increased susceptibility of women to the trigger of stress exposure. FHA appears today as a complex disease resulting from the combination of genetic predisposition, environmental factors, and epigenetic changes. Furthermore, the genetic background of FHA allows for the hypothesis of a male counterpart. Despite the paucity of data, preliminary findings indicate that an equivalent condition of FHA exists in men, warranting further investigation. This narrative review aims to summarize the recent genetic evidence contributing to the pathophysiology of FHA and to raise awareness on a possible male counterpart.
Subjects with hemophagocytic lymphohistiocytosis (HLH) often have life-threatening complications at the time of diagnosis resulting from excessive inflammation. This excessive inflammation is driven by abnormally high levels of cytokines--proteins involved in inflammation. Standard therapy for HLH does not directly target these cytokines. Tocilizumab is a medicine that blocks one of the cytokines that is elevated in patients with HLH.

This is an open-label single-arm uncontrolled trial with biologic endpoint. This study will use tocilizumab in subjects with HLH and high cytokine levels in an attempt to decrease the damage caused by these proteins. All subjects will receive standard therapy, in addition to tocilizumab. We hypothesize the tocilizumab will decrease levels of certain important cytokines. This may make it easier to treat subjects with HLH overall.

TCZ will be administered as a single dose (8mg/kg) intravenously. Eligible subjects will be inpatients at the Children's Hospital of Philadelphia (CHOP) main campus. 10 subjects with HLH will be enrolled. All subjects will be initiated on standard HLH-directed treatment. Cytokine levels \[including serum interferon (IFN-γ) and interleukin (IL-6)\] will be monitored, in addition to other laboratory and clinical markers of HLH disease activity.
The invention belongs to the technical field of traditional Chinese medicines and discloses medicinal liquor for treating cervical spondylosis and a preparation method thereof. The medicinal liquor consists of 200-400 g of baked sheep bone, 5-10 g of borneol, 5 g of frankincense, 5 g of myrrh and 50 ml of 60-degree liquor. The medicinal liquor is prepared through the steps of cleaning and drying the baked sheep bone, the borneol, the frankincense and the myrrh, and soaking the baked sheep bone, the borneol, the frankincense and the myrrh into the 60-degree liquor at a normal temperature for 20 days without exposure to light and air. The medicinal liquor is used for external application, requires less raw materials and is easy to prepare. The medicinal liquor is essentially used for treating all types of cervical spondylosis and has the effects of promoting blood circulation to remove meridian obstruction, removing pathogenic wind and dampness, and relaxing muscles and strengthening bones. At the same time, the medicinal liquor provided by the invention has the advantages of easy application and quick effect, thereby meeting the needs of patients.